2021
DOI: 10.1007/s41669-021-00295-2
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review

Abstract: This review discusses the methodological challenges to the evaluation of advanced therapy medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence (NICE). We analysed the health technology appraisals (both published and in development) of ATMPs conducted by NICE in England until July 2021. A total of 14 health technology appraisals of ATMPs were included, of which two were in development and 12 had been published. There were ten gene therapy products (talimogene laherparepvec [TA4… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 18 publications
0
4
0
Order By: Relevance
“…(2) The second hypothesis is that uncertainty paragraphs are more likely to appear in appraisals for RDTs that are classified as ATMPs by the European Medicines Agency compared to non-ATMPs. This is because of uncertainties and limitations in the clinical data and economic evaluations of ATMPs, including trial follow-up periods that are usually too short to observe long-term treatment effects, small sample sizes, and single-arm studies ( 39 ; 40 ).…”
Section: Methodsmentioning
confidence: 99%
“…(2) The second hypothesis is that uncertainty paragraphs are more likely to appear in appraisals for RDTs that are classified as ATMPs by the European Medicines Agency compared to non-ATMPs. This is because of uncertainties and limitations in the clinical data and economic evaluations of ATMPs, including trial follow-up periods that are usually too short to observe long-term treatment effects, small sample sizes, and single-arm studies ( 39 ; 40 ).…”
Section: Methodsmentioning
confidence: 99%
“…[145][146][147] Indeed, at this point the domains of thalassemia and sickle cell anemia have raised more pharma interest for gene editing approaches. [148][149][150] On another level, for the context of gene therapy or gene editing approaches for IEI, strategies are needed to allow patients affected by ultrarare conditions to benefit from cutting-edge technological advancements in therapeutics. 151 Molecular and cellular therapies have intrinsically high development costs, which are mostly covered by research grants or charity up to the stage of first clinical trials.…”
Section: Tre Atment Of Inborn Error S Of Immunit Y: Trial S and Tribu...mentioning
confidence: 99%
“…Several gene therapy clinical trials are currently running for X‐linked SCID, RAG1 SCID, ADA‐SCID, Artemis‐SCID, Wiskott‐Aldrich syndrome (WAS), CGD, leukocyte adhesion deficiency type I (LAD I), and Immune dysregulation polyendocrinopathy enteropathy X linked (IPEX) syndrome, while the first gene therapy trials based on gene editing with clustered regularly interspaced short palindromic repeats (CRISPR) instead of viral vector transduction are underway in sickle cell disease and beta thalassemia 145–147 . Indeed, at this point the domains of thalassemia and sickle cell anemia have raised more pharma interest for gene editing approaches 148–150 …”
Section: Treatment Of Inborn Errors Of Immunity: Trials and Tribulationsmentioning
confidence: 99%
“…Over the years, an increasing number of ATMP clinical trials are conducted for treatment of cancer, genetic disorders, cartilage defects and metabolic diseases as they have potential curative outcomes and also a long-lasting therapeutic effect. 4 …”
Section: Atmp and Their Challengesmentioning
confidence: 99%